Loading
companiesCompany
Simcere Pharmaceutical
Simcere is a Nanjing-based pharmaceutical company whose oncology arm, Simcere Zaiming, is running the phase 3 SIMRISE trial of the oral SERD SIM0270 with everolimus in ER-positive breast cancer and markets the anti-PD-1 antibody enlonstobart in China.
Also called: Jiangsu Simcere Pharmaceutical Co., Ltd.Simcere Zaiming
Overview
Simcere Pharmaceutical Group, based in Nanjing and listed in Hong Kong, sells medicines across oncology, neurology and autoimmune disease in China and runs its cancer research through the subsidiary Simcere Zaiming. Its oncology portfolio includes enlonstobart, an anti-PD-1 antibody approved in China for previously treated cervical cancer, the Chinese rights to the myeloprotective drug trilaciclib, and SIM0270, an oral selective oestrogen receptor degrader in the phase 3 SIMRISE trial with everolimus for ER-positive, HER2-negative advanced breast cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Nanjing, CN
Scorecard
All companies#192of 1244 companies, score 31
- approved products +6
- phase 3 +3
- modalities +2
- regions +1
- registry trials +19
1 approved, 1 in phase 3, 0 earlier, 0 targets, 92 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 3small molecule (structure undisclosed or not yet in PubChem)
SIM0270 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Simcere Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
ApprovedRecombinant angiogenesis inhibitor protein
Endostar is Simcere's recombinant endostatin, approved in China in 2005 with chemotherapy for advanced non-small-cell lung cancer, one of the first angiogenesis inhibitors approved anywhere.
Similar pages
cancers
fronts
drugs
ApprovedRecombinant angiogenesis inhibitor protein
Phase 3small molecule (structure undisclosed or not yet in PubChem)
trials
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerA Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural EffusionsA Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Cthe Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib